Clostridium Difficile Virulence Mechanism Study (CDVM Study)

Last updated: August 30, 2018
Sponsor: Chinese University of Hong Kong
Overall Status: Active - Recruiting

Phase

N/A

Condition

Clostridium Difficile-associated Diarrhea

Gastroenteritis

Treatment

N/A

Clinical Study ID

NCT03654872
CDVMProtocol
  • Ages > 18
  • All Genders

Study Summary

This study is an observational study to collect stool samples from patients with Clostridium difficile infection (CDI) to investigate the virulence mechanisms of C. difficile ribotypes in Hong Kong, mainly ribotype 002. No intervention is involved.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with a confirmed diagnosis of CDI, as documented by diarrheal symptoms andpositive stool test result for C. difficile toxin or toxigenic C. difficile, orcolonoscopic findings of pseudomembranous colitis (PMC).

  • Patients aged over or equal to 18 years old.

  • Patients able and willing to provide informed consent.

Exclusion

Exclusion Criteria:

  • Patients with concomitant infection by other microbes such as Salmonella,Campylobacter, Vibrio, Shigella, and Escherichia coli.

  • Patients under 18 years old.

  • Patients who cannot give consent.

Study Design

Total Participants: 227
Study Start date:
June 30, 2018
Estimated Completion Date:
May 30, 2019

Study Description

This is an observational study to collect stool samples from patients with Clostridium difficile infection (CDI), aims to (1) to investigate the virulence mechanisms of C. difficile ribotype 002, by analysing its growth, cytotoxicity, and metabolite production in vitro and in vivo. The investigators also aim (2) to compare these virulence mechanisms with other common ribotypes in Asia, and (3) to correlate these with important clinical outcomes. The results of this study will have a major significance to the medical and scientific community. The results of this study will have a major significance to the medical and scientific community. The mechanistic data will point to important molecular pathways that can be targeted for novel therapies; whereas the phenotypic data will inform the investigators of its virulence and therefore will be useful for disease surveillance and public health interventions. The identified toxin(s) and metabolite(s) may be useful as prognostic biomarkers to stratify patients with different outcomes, as patients with a worse outcome may require more aggressive therapy. Given the prevalence and severity of this ribotype, the results will be useful for gastroenterologists, microbiologists, infectious diseases physicians and public health specialists in the Asia Pacific region.

Connect with a study center

  • Prince of Wales Hospital, The Chinese University of Hong Kong

    Hong Kong,
    Hong Kong

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.